Showing results (201-210 of 335) with videos related to
Sort By:
Pageof 34
JCI Insight|April 10, 2020
Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cellsSisi Deng, Zhichen Sun, Jian Qiao, et al.Cell Reports|August 23, 2018
Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune EvasionXiaojuan Liu, Longchao Liu, Zhenhua Ren, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 17, 2015
Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 PhenotypeMeng Xu, Mingyue Liu, Xuexiang Du, et al.Nature Medicine|September 1, 2015
CD47 blockade triggers T cell-mediated destruction of immunogenic tumorsXiaojuan Liu, Yang Pu, Kyle Cron, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 4, 2016
Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic VaccinationDanming Zhu, Longchao Liu, Dan Yang, et al.Science Translational Medicine|January 28, 2021
A chimeric antigen receptor with antigen-independent OX40 signaling mediates potent antitumor activityHuihui Zhang, Fanlin Li, Jiang Cao, et al.The Journal of Experimental Medicine|June 18, 2003
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanismXingluo Liu, Jian Xin Gao, Jing Wen, et al.Nature Communications|September 25, 2020
PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockadeQi Peng, Xiangyan Qiu, Zihan Zhang, et al.Journal of Clinical Medicine|July 27, 2022
A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron StrainsZhiren Zhang, Qiaren He, Wei Zhao, et al.Nature Immunology|July 31, 2012
OX40 signaling favors the induction of T(H)9 cells and airway inflammationXiang Xiao, Savithri Balasubramanian, Wentao Liu, et al.Pageof 34